ReviewBMC cancer2016
Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review.
Review in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- IPDMA - RADICAL - NSCLC: individual participant data meta-analysis and systematic review of radical local therapy for oligometastatic NSCLC.BMJ open respiratory research · 2025Pooled it
- Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.Journal of the National Cancer Institute · 2021Pooled it
- Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review.BMC urology · 2019Pooled it
- Health-Related Quality of Life in Advanced Non-small Cell Lung Cancer: A Methodological Appraisal Based on a Systematic Literature Review.Frontiers in oncology · 2019Pooled it
- Trial
- Methodology of analysis of cognitive impairment in longitudinal randomized clinical trials in oncology: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- What Cachexia-Related Outcomes Are Measured in Lung Cancer Chemotherapy Clinical Trials?Cancers · 2025Article
- MicroRNA-98: the multifaceted regulator in human cancer progression and therapy.Cancer cell international · 2024Review
- Analyses of quality of life in cancer drug trials - a review of measurements and analytical choices in post-reimbursement studies.BMC cancer · 2024Review
- 15 years of patient-reported outcomes in clinical trials leading to GU cancer drug approvals: a systematic review on the quality of data reporting and analysis.EClinicalMedicine · 2024Article
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study.Frontiers in pharmacology · 2024Article
- Time to deterioration of patient-reported outcomes in non-small cell lung cancer: exploring different definitions.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Functional status in older patients with lung cancer: an observational cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Observational
- Crucial Roles of miR-625 in Human Cancer.Frontiers in medicine · 2022Review
- Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study.Journal of medical Internet research · 2021Article
- Review
- Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.Neuro-oncology practice · 2021Article
- MicroRNA-30e inhibits proliferation and invasion of non-small cell lung cancer via targeting SOX9.Human cell · 2019Article
- Determining clinically important differences in health-related quality of life in older patients with cancer undergoing chemotherapy or surgery.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth-related quality of life (HRQoL) is recognized as a component endpoint for cancer therapy approvals. The aim of this review was to evaluate the methodology of HRQoL analysis and reporting in phase III clinical trials of first-line chemotherapy in advanced non-small cell lung cancers (NSCLC).
methodsA search in MEDLINE databases identified phase III clinical trials in first-line chemotherapy for advanced NSCLC, published between January 2008 to December 2014. Two authors independently extracted information using predefined data abstraction forms.
resultsA total of 55 phase III advanced NSCLC trials were identified. HRQoL was declared as an endpoint in 27 studies (49%). Among these 27 studies, The EORTC questionnaire Quality of Life Questionnaire C30 was used in 13 (48%) of the studies and The Functional Assessment of Cancer Therapy-General was used in 12 (44%) trials. The targeted dimensions of HRQoL, the minimal clinically important difference and the statistical approaches for dealing with missing data were clearly specified in 13 (48.1%), 9 (33.3%) and 5 (18.5%) studies, respectively. The most frequent statistical methods for HRQoL analysis were: the mean change from baseline (33.3%), the linear mixed model for repeated measures (22.2%) and time to HRQoL score deterioration (18.5%). For each targeted dimension, the results for each group, the estimated effect size and its precision were clearly reported in 4 studies (14.8%), not clearly reported in 11 studies (40.7%) and not reported at all in 12 studies (44.4%).
conclusionsThis review demonstrated the weakness and the heterogeneity of the measurement, analysis, and reporting of HRQoL in phase III advanced NSCLC trials. Precise and uniform recommendations are needed to compare HRQoL results across publications and to provide understandable messages for patients and clinicians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.